지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2021.1
- 수록면
- 345 - 352 (8page)
이용수
초록· 키워드
오류제보하기
ObjectiveDoes the timing of cabergoline administration impact the rate of mild/moderate ovarian hyperstimulation syndromein women with a GnRH agonist trigger?MethodsWe conducted a retrospective cohort analysis of 285 in-vitro fertilization patients at risk of OHSS who received a GnRHagonist trigger from 2011 to 2019 at McGill University Health Centre. Group 1 (Trig, n=101) began taking cabergoline0.5 mg orally for 7 days at the time of GnRH agonist trigger, while Group 2 (Retriev, n=184) started taking cabergolineon the day of oocyte retrieval. The rates of OHSS were then compared between the groups using analysis of varianceand chi-square analysis, where appropriate. ResultsThe baseline demographic characteristics of the two groups were similar. Trig appeared to be at a slightly higherrisk of OHSS based on a significantly higher antral follicle count (20.2±4.2 vs. 19.0±4.3; P=0.02), higher number ofstimulated follicles >10 mm at trigger (25.7±7.0 vs. 22.8±8.3, P=0.003), and higher peak serum E2 level (17,325±2,542vs. 14,822±3,098; P=0.0001). The Trig group had lower rates of mild and moderate OHSS (24% vs. 36%; P=0.045). Neither group had any patients who developed severe OHSS. Trig had fewer patients presenting with pelvic free fluid(13% vs. 23%; P=0.03), lower hematocrit (37.8±4.8% vs. 40.5±4.2%; P=0.0001), higher albumin concentrations (30.4±2.7vs. 29.5±2.0; P=0.01), and lower potassium concentrations (3.9±0.5 vs. 4.2±0.7; P=0.0002). ConclusionCabergoline at the time of trigger as compared to the time of collection should be investigated to assess its role inreducing the rates of mild/moderate OHSS.
목차
등록된 정보가 없습니다.
참고문헌 (1)
참고문헌 신청
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
The use of gonadotropin-releasing hormone antagonist post-ovulation trigger in ovarian hyperstimulation syndrome
Clinical and experimental reproductive medicine : CERM
2017 .01
-
Gonadotropin releasing hormone antagonist administration for treatment of early type severe ovarian hyperstimulation syndrome: a case series
Obstetrics & Gynecology Science
2017 .01
-
Early gonadotropin-releasing hormone antagonist protocol in women with polycystic ovary syndrome: A preliminary randomized trial
Clinical and experimental reproductive medicine : CERM
2018 .01
-
The Risk Factors and Pregnancy Outcomes of 48 Cases of Heterotopic Pregnancy from a Single Center
Journal of Korean Medical Science
2016 .01
-
Factors influencing serum progesterone level on triggering day in stimulated in vitro fertilization cycles
Clinical and experimental reproductive medicine : CERM
2015 .01
-
Preterm Ovarian Hyperstimulation Syndrome
Neonatal medicine
2015 .01
-
Efficacy of corifollitropin alfa followed by recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist protocol for Korean women undergoing assisted reproduction
Clinical and experimental reproductive medicine : CERM
2015 .01
-
Serum Cholesterol Level Changes during Gonadotropin-Releasing Hormone-Agonist Therapy in Premenopausal Female Patients with Breast Cancer
대한폐경학회지
2024 .08
-
Clinical outcomes of frozen embryo transfer cycles after freeze-all policy to prevent ovarian hyperstimulation syndrome
Obstetrics & Gynecology Science
2018 .01
-
N-glycoproteomic analysis of human follicular fluid during natural and stimulated cycles in patients undergoing in vitro fertilization
Clinical and experimental reproductive medicine : CERM
2017 .01
-
청소년에서 구강건강관련 자기효능감과 사회적 지지가 구강건강관련 삶의 질에 미치는 영향
대한구강보건학회지
2023 .03
-
Dual trigger with gonadotropin-releasing hormone agonist and recombinant human chorionic gonadotropin improves the outcome of intrauterine insemination
Obstetrics & Gynecology Science
2022 .03
-
The meaning of anti-Mullerian hormone levels in patients at a high risk of poor ovarian response
Clinical and experimental reproductive medicine : CERM
2016 .01
-
Concurrent Gonadotropin-Releasing Hormone Agonist Administration with Chemotherapy Improves Neoadjuvant Chemotherapy Responses in Young Premenopausal Breast Cancer Patients
Journal of Breast Cancer
2015 .01
-
Association between different dual trigger dosages and in vitro fertilization results in patients with patientoriented strategies encompassing individualized oocyte number group IV
Obstetrics & Gynecology Science
2022 .03
-
A retrospective analysis of the follicle-stimulating hormone starting dose in expected normal responders undergoing their first in vitro fertilization cycle: proposed dose versus empiric dose
Clinical and experimental reproductive medicine : CERM
2018 .01
-
Two Cases of Primary Ovarian Insufficiency Accompanied by High Serum Anti-Mullerian Hormone Levels and Preservation of Ovarian Follicles
대한폐경학회지
2020 .01
-
Transabdominal follicular aspiration in an in vitro fertilization cycle: experiences with an unusual but necessary intervention in a resource-limited setting
Clinical and experimental reproductive medicine : CERM
2016 .01
-
In vitro fertilization outcome in women with diminished ovarian reserve
Obstetrics & Gynecology Science
2017 .01
-
Effect of trigger day serum luteinising hormone levels on the in-vitro fertilization outcome: an observational study
Obstetrics & Gynecology Science
2024 .03
이 논문의 저자 정보
최근 본 자료
댓글(0)
0